Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Non-Current Assets (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Non-Current Assets for 6 consecutive years, with $71.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 251.7% year-over-year to $71.8 million, compared with a TTM value of $184.6 million through Dec 2025, up 108.81%, and an annual FY2025 reading of $71.8 million, up 251.7% over the prior year.
  • Non-Current Assets was $71.8 million for Q4 2025 at SAB Biotherapeutics, up from $70.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $116.2 million in Q3 2021 and bottomed at $20.4 million in Q4 2024.
  • Average Non-Current Assets over 5 years is $43.9 million, with a median of $28.2 million recorded in 2022.
  • The sharpest move saw Non-Current Assets crashed 73.89% in 2022, then skyrocketed 251.7% in 2025.
  • Year by year, Non-Current Assets stood at $30.9 million in 2021, then dropped by 6.92% to $28.8 million in 2022, then dropped by 13.1% to $25.0 million in 2023, then fell by 18.5% to $20.4 million in 2024, then surged by 251.7% to $71.8 million in 2025.
  • Business Quant data shows Non-Current Assets for SABS at $71.8 million in Q4 2025, $70.2 million in Q3 2025, and $20.8 million in Q2 2025.